The expanded partnership will see Lonza extending the manufacturing of the drug substance for the Covid-19 vaccine by Moderna. It will also include the installation of a new manufacturing line for the production of drug substances at Lonza’s site in Geleen.
Swiss pharmaceutical company Lonza has announced on June 2, that it has expanded its collaboration with biotech company Moderna.
This comes after the announcement of a 10-year strategic collaboration agreement signed between both companies in May 2020 to enable the manufacture of the Moderna Covid-19 vaccine and additional Moderna products in future.
